Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12 Other hematologic neoplasm 5 Lymphoid 4 Gastrointestinal 4 Dermatologic 4 Plasma cell 3 Myeloid 2 Tumor-Agnostic 1 Thoracic 1 Other 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 547 Pemetrexed 402 Cisplatin 400 Paclitaxel 272 Docetaxel 255 Gemcitabine 218 pembrolizumab 190 Bevacizumab 190 Erlotinib Hydrochloride 184 Radiotherapy 179 Etoposide 147 durvalumab 140 Nivolumab 134 Drug Therapy 127 osimertinib 106 atezolizumab 92 Gefitinib 74 Radiosurgery 71 anlotinib 69 Vinorelbine 68 tislelizumab 52 Irinotecan 51 Ipilimumab 50 130-nm albumin-bound paclitaxel 49 Taxes 48 Surgical Procedures, Operative 46 Cetuximab 46 sintilimab 45 Albumin-Bound Paclitaxel 45 apatinib 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tablets × Thoracic × Clear all

NCT00080080 2007-06-08

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Point Therapeutics

Phase 2 Completed

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡